Cycle Pharmaceuticals proposes to acquire Vanda Pharmaceuticals for $8.00 per share
Acquiring Company
Cycle Pharmaceuticals
Acquired Company
Vanda Pharmaceuticals
Cambridge
WashingtonBiotechnologyHealth CarePharmaceuticalBiotechnologyHealth CareMedicalTherapeuticsPharmaceuticalBiopharmaDescription
Cycle Pharmaceuticals Ltd has proposed to acquire 100% of Vanda Pharmaceuticals, Inc.'s issued and outstanding shares for a cash consideration of $8.00 per Vanda share, representing a total cash consideration of $466 million. This proposal delivers immediate, compelling, and certain cash value for Vanda shareholders with a highly attractive premium, marking a 98% premium above Vanda's closing share price on April 16, 2024.
Quick answer
Cycle Pharmaceuticals is acquiring Vanda Pharmaceuticals, announced June 6, 2024. Cycle Pharmaceuticals is based in Cambridge, England, United Kingdom.
- How much did Cycle Pharmaceuticals pay for Vanda Pharmaceuticals?
- The deal value was not disclosed.
- What does Cycle Pharmaceuticals do?
- Cycle Pharmaceuticals was founded in 2012 with the sole aim of delivering drug treatments and product support to the underserved rare disease patient community.
- Where are Cycle Pharmaceuticals and Vanda Pharmaceuticals based?
- Cycle Pharmaceuticals is based in Cambridge, England, United Kingdom. Vanda Pharmaceuticals is based in Washington, District Of Columbia, United States.
- Who are the decision-makers at Cycle Pharmaceuticals?
- Fundz holds 1 contact at Cycle Pharmaceuticals. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Pharmaceutical and Medical
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- AbbVie finalizes acquisition of Landos Biopharma, Inc. to advance treatment for ulcerative colitis and Crohn's disease (May 23, 2024)
- Harmony Biosciences acquires Epygenix Therapeutics, Inc. to expand rare epilepsy franchise (April 30, 2024)
- Eli Lilly acquires Morphic Holding for $3.2B, focusing on IBD treatment opportunities, $3.2B (July 8, 2024)
- Lilly completes acquisition of Morphic to enhance immunology pipeline (July 8, 2024)
- Ligand Pharmaceuticals to acquire APEIRON Biologics AG to enhance royalty portfolio (July 8, 2024)
- Incyte completes acquisition of Escient Pharmaceuticals to strengthen its Inflammation and Autoimmunity portfolio (May 30, 2024)
Who to call at Cycle Pharmaceuticals, and when
When Cycle Pharmaceuticals changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Cycle Pharmaceuticals raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Cycle Pharmaceuticals, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Cycle Pharmaceuticals. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Cycle Pharmaceuticals makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Vanda Pharmaceuticals?
Vanda Pharmaceuticals was acquired by Cycle Pharmaceuticals, based in Cambridge. The deal was reported on June 6, 2024. Cycle Pharmaceuticals was founded in 2012 with the sole aim of delivering drug treatments and product support to the underserved rare disease patient community. Cycle Pharmaceuticals is privately held and operates in Biotechnology.
When did Cycle Pharmaceuticals acquire Vanda Pharmaceuticals?
Cycle Pharmaceuticals's acquisition of Vanda Pharmaceuticals was reported on June 6, 2024. Cycle Pharmaceuticals Ltd has proposed to acquire 100% of Vanda Pharmaceuticals, Inc.'s issued and outstanding shares for a cash consideration of $8.00 per Vanda share, representing a total cash consideration of $466 million. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Vanda Pharmaceuticals do?
Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. It is publicly traded (VNDA), operating in Biotechnology, and is based in Washington.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.